logo
Plus   Neg
Share
Email

Lupin Reports European Commission Approval Of NaMuscla - Quick Facts

Lupin (LUPIN) announced that the European Commission has approved NaMuscla (mexiletine) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders. Lupin is preparing for the launch of NaMuscla, which will occur in the initial markets of Germany and the UK in the first quarter of 2019. The company has partnering discussions ongoing for commercialization of NaMuscla in European territories outside Germany and the UK.

The company noted that the approval makes NaMuscla the first treatment to be licensed throughout the EU for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT